Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials

G Wright, R L Manser, G Byrnes, D Hart, D A Campbell

Background: Surgery is considered the treatment of choice for patients with resectable stage I and II (and some patients with stage IIIA) non-small cell lung cancer (NSCLC), but there have been no previously published systematic reviews.

Methods: A systematic review and meta-analysis of randomised controlled trials was conducted to determine whether surgical resection improves disease specific mortality in patients with stages I–IIIA NSCLC compared with non-surgical treatment, and to compare the efficacy of different surgical approaches.

Results: Eleven trials were included. No studies had untreated control groups. In a pooled analysis of three trials, 4 year survival was superior in patients undergoing resection with stage I–IIIA NSCLC who had complete mediastinal lymph node dissection compared with lymph node sampling (hazard ratio estimated at 0.78 (95% CI 0.65 to 0.93)). Another trial reported an increased rate of local recurrence in patients with stage I NSCLC treated with limited resection compared with lobectomy. One small study reported a survival advantage among patients with stage IIIA NSCLC treated with chemotherapy followed by surgery compared with chemotherapy followed by radiotherapy. No other trials reported significant improvements in survival after surgery compared with non-surgical treatment.

Conclusion: It is difficult to draw conclusions about the efficacy of surgery for locoregional NSCLC because of the small number of participants studied and methodological weaknesses of the trials. However, current evidence suggests that complete mediastinal lymph node dissection is associated with improved survival compared with node sampling in patients with stage I–IIIA NSCLC undergoing resection.
randomisation was also assessed as described by Jadad et al.\textsuperscript{13} The reviewers assessed whether there was blinding of outcome assessment and adequate description of withdrawals.\textsuperscript{10} Finally, an assessment was made as to whether the trial results used intention to treat analysis.\textsuperscript{11,12} The authors of included studies were asked to verify assessments of study methodology where possible.

**Data extraction**

Data extracted by one of the reviewers (RM) was entered in the Cochrane Collaboration software (Review Manager Version 4.2 for Windows, Cochrane Collaboration, Oxford, UK, 2002). Authors of included studies were asked to confirm the data extracted where possible. A second reviewer (GW) extracted data from graphs, where necessary, for main study outcomes.

**Outcome measures**

The main outcomes were overall or disease specific survival at 2, 3, 4 or 5 years. Secondary outcomes included progression free survival or recurrence rates (local, distant or both), postoperative mortality or treatment related death, and tests of respiratory function.

**Quantitative data synthesis**

Outcomes were pooled using the Review Manager and a pooled relative risk was calculated with 95% confidence intervals. Homogeneity of effect sizes among pooled studies was tested using the $\chi^2$ statistic for homogeneity with $p<0.1$ as the level for significance. In the absence of significant statistical heterogeneity, a fixed effects model was used for the pooled analysis.

Because of the broad inclusion criteria it was inappropriate to pool results for all studies. A pooled analysis was conducted on three trials comparing complete mediastinal lymph node dissection (CMLND) with systematic sampling (SS) of nodes.\textsuperscript{13-15} A separate pooled analysis was planned on trials comparing chemotherapy plus surgery with sequential chemotherapy plus radiotherapy in patients with stage IIIA NSCLC.\textsuperscript{16-17} For the meta-analysis of survival data, the pooled log hazard ratio was calculated as a weighted average of the individual trial log hazard ratios, with weights inversely proportional to the variance of the log hazard ratio of each trial using the Review Manager software.\textsuperscript{18,19} None of these studies reported a hazard ratio and variance that would be suitable for meta-analysis. The methods described by Parmar et al were used to estimate the hazard ratios and variance indirectly from confidence intervals or $p$ values for the log rank test.\textsuperscript{20} For one study the hazard ratio was extracted from the survival curves using the methods of Parmar et al.\textsuperscript{14-18}

Briefly, in this case the time axis of the survival curve was split into equal non-overlapping time periods and the log hazard ratio was estimated for each equal time period and then combined in a stratified way across intervals to obtain an overall log hazard ratio. For a further study the authors\textsuperscript{21} provided original data enabling hazard ratio and variance calculation using the Cox proportional hazards model (Stata Version 6.0 for Windows, Stata Corporation, Texas, 1999).

For the meta-analysis of studies comparing complete mediastinal lymph node dissection with systematic sampling of mediastinal lymph nodes, follow up for two of the trials was restricted to 4 years so that the time periods of follow up would be comparable between pooled studies.\textsuperscript{14,15} For the remaining studies a hazard ratio was calculated where possible; otherwise, survival at 2, 3, 4 or 5 years (depending on the data reported for the primary studies) was assessed by entering the number of participants surviving in Review Manager, but a pooled analysis was not conducted.\textsuperscript{13} Where possible, the statistical analysis was conducted in accordance with intention to treat principles. The level of agreement between reviewers evaluating studies for inclusion was assessed using simple kappa statistics.

**RESULTS**

**Search for trials**

1181 citations were identified by the MEDLINE search, 70 by searching the Cochrane Central Register of Controlled Trials, and approximately 430 citations were identified by the EMBASE search. After review of abstracts selected from the search of electronic databases, bibliographies and hand searches, 27 papers were selected for full text review. Eleven trials (some with multiple citations) were selected for inclusion in the review.\textsuperscript{12-17,20-28} One of these controlled trials was not described as randomised in the report but the primary author confirmed that the study was randomised.\textsuperscript{26} No trials were identified that included an untreated control group. Ongoing trials were also identified but results are not yet available.\textsuperscript{29-31} Two reviewers (RM and GW) agreed on the inclusion of primary studies or experts.

**Study characteristics**

Trials comparing surgery (± other treatment) with non-surgical treatment arm

Several trials with diverse study designs were included in this category (table 1). Two trials compared chemotherapy followed by surgery with chemotherapy followed by
radiotherapy in patients with stage IIIA NSCLC. In one study the inclusion criteria included the demonstration of pathological N2 disease but the TNM status of participants was not well described in the other study.

Studies comparing different surgical approaches for lung cancer

**Mediastinal lymphadenectomy (n = 3 studies)**

Three studies compared CMLND with SS in patients with resectable NSCLC. Two of these were conducted in patients with resectable stages I–III.

One was limited to patients with peripheral NSCLC less than 2 cm in diameter and without evidence of metastasis. For this review the terminology recommended by Keller has been used. SS refers to the routine biopsy of lymph nodes at the levels specified by the authors and CMLND refers to the routine removal of all ipsilateral lymph node bearing tissue. Further details are shown in table 2. One reviewer (GW) determined that SS was performed in similar fashion in the three studies, and CMLND was performed according to the techniques of Naruke et al and Martini et al. In these studies patients with involvement of N2 nodes were offered adjuvant

---

**Table 1** Trials comparing surgery (± other treatment) with non-surgical treatment arm

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Subjects</th>
<th>Intervention</th>
<th>Control</th>
<th>Number randomised</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRC, UK (1954–64)</td>
<td>Histologically confirmed, clinically locoregional lung cancer*</td>
<td>Thoracotomy and radical resection of tumour with hilar and mediastinal nodes</td>
<td>Radiotherapy (45 Gy to primary and mediastinum)</td>
<td>58</td>
<td>Overall 4 year survival</td>
</tr>
<tr>
<td>NCI, USA (1963–64)</td>
<td>Histologically confirmed inoperable locally advanced lung cancer, *potentially operable after radiotherapy</td>
<td>Radiotherapy (40 Gy to primary and mediastinum) followed by surgery</td>
<td>Radiotherapy only (40 Gy to primary and mediastinum)</td>
<td>425</td>
<td>Inoperable patients given radiotherapy, 152 randomised, Overall and disease free 5 year survival</td>
</tr>
<tr>
<td>National Cancer Institute of Canada Clinical Trials Group (before 1997)†</td>
<td>Stage IIIA NSCLC (pN2) fit for surgery, ECOG ≤2‡</td>
<td>Induction chemotherapy followed by surgical resection</td>
<td>Radiotherapy (60 Gy total, 50 Gy to primary tumour and mediastinum, plus 10 Gy to reduced target volume)</td>
<td>31</td>
<td>Overall 2 year survival</td>
</tr>
<tr>
<td>RTOG 89–01 trial, USA (1990–4)‡</td>
<td>Stage IIA NSCLC (pN2M0) with no mediastinoscopy</td>
<td>Induction cisplatin based chemotherapy followed by surgical resection</td>
<td>Induction cisplatin based chemotherapy followed by radiotherapy (64 Gy)</td>
<td>73</td>
<td>Overall 4 year survival</td>
</tr>
<tr>
<td>University of Athens, Greece, (1998–91)†</td>
<td>Stage IIA NSCLC (exact TNM not stated) Karnofsky performance status 70–90</td>
<td>4 cycles cisplatin based chemotherapy followed by surgical resection</td>
<td>6 cycles of cisplatin based chemotherapy followed by radiotherapy (50 Gy)</td>
<td>60</td>
<td>Overall 5 year survival</td>
</tr>
<tr>
<td>North American Intergroup trial 0139 (RTOG 93–09), (1994–2001)‡</td>
<td>Stage T1–3 pN2M0 NSCLC with potentially resectable stage IIA or IB NSCLC, surgical resection technically feasible at randomisation</td>
<td>Concurrent cisplatin and etoposide and radiotherapy (45 Gy) followed by surgical resection</td>
<td>Concurrent cisplatin and etoposide and radiotherapy (61 Gy)</td>
<td>429</td>
<td>Progression free and overall 3 year survival</td>
</tr>
</tbody>
</table>

*Includes some cases of small cell lung cancer.
‡ECOG, Eastern Cooperative Oncology Group performance status (0 = asymptomatic, 1 = capable of light work, 2 = less than half daylight hours in bed).
†RTOG, Radiation Therapy Oncology Group.

**Table 2** Trials comparing different surgical approaches for lung cancer

<table>
<thead>
<tr>
<th>Study and year</th>
<th>Subjects</th>
<th>Intervention</th>
<th>Control</th>
<th>Number randomised</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yamaguchi University, Japan (1992–6)§</td>
<td>Clinical stage IA NSCLC, no mediastinoscopy</td>
<td>Video-assisted thorascoscopic lobectomy</td>
<td>Thoracotomy and conventional lobectomy</td>
<td>100</td>
<td>Overall 5 year survival</td>
</tr>
<tr>
<td>Lung Cancer Study Group Trial, North America (1982–8)§</td>
<td>T1N0M0 peripheral NSCLC fit for lobectomy</td>
<td>Limited resection (wedge resection or segmentectomy, i.e. less than lobectomy)</td>
<td>Conventional lobectomy</td>
<td>276</td>
<td>Overall 5 year survival, local recurrence rate, death with cancer rate, pulmonary function</td>
</tr>
<tr>
<td>University of Munich and Central Hospital, Gauting, Germany (1989–91)§</td>
<td>Resectable NSCLC (stages I–IIA)</td>
<td>Thoracotomy, surgical resection, complete mediastinal lymph node dissection</td>
<td>Thoracotomy, surgical resection, systematic sampling of mediastinal lymph nodes</td>
<td>201</td>
<td>Overall and progression free survival (median follow up 47 months)</td>
</tr>
<tr>
<td>Yamaguchi University, Japan (1985–92)§</td>
<td>Peripheral NSCLC &lt; 2 cm diameter, mediastinal and hilar lymph nodes &lt; 1 cm on CT (no mediastinoscopy)</td>
<td>Thoracotomy, surgical resection, complete mediastinal lymph node dissection</td>
<td>Thoracotomy, surgical resection, systematic sampling of mediastinal lymph nodes</td>
<td>115</td>
<td>Overall 5 year survival</td>
</tr>
<tr>
<td>Sun Yat-Sen University of Medical Sciences, Guangzhou, China (1989–95)§</td>
<td>Pathologically confirmed NSCLC, clinical stages I–IIA, age &lt; 71 years</td>
<td>Thoracotomy, surgical resection, complete mediastinal lymph node dissection</td>
<td>Thoracotomy, surgical resection, systematic sampling of mediastinal lymph nodes</td>
<td>532</td>
<td>Overall 5 year survival</td>
</tr>
</tbody>
</table>
radiotherapy to the mediastinum postoperatively; however, in one study patient uptake in those with N2 disease in both arms was only about 30% according to the author.²³

Limited resection (wedge excision or segmentectomy) versus lobectomy

In a multi-institutional North American study, individuals with proven or suspected T1N0 peripheral NSCLC were randomised to either limited resection (thoracotomy with wedge resection or segmentectomy) versus lobectomy.²² All patients were able to tolerate a lobectomy as assessed by cardiopulmonary function. Sublobar resections of up to three segments or wedge resections encompassing the tumour and 2 cm of lung were allowed, at the surgeon’s discretion. Pathological stage was confirmed before randomisation at the time of surgery by frozen section. After resection the completeness of resection was assessed by frozen section. After resection the completeness of resection was assessed by frozen section and, if the resection was incomplete or the tumour was found to be of a higher stage, the surgeon was required to complete the lobectomy. 276 were randomised at the time of surgery but there were 29 exclusions after randomisation.²²

Video assisted thoracoscopic surgery (VATS) lobectomy versus conventional lobectomy

One study compared 5 year survival in patients randomised to VATS lobectomy versus conventional lobectomy in patients with clinical stage I A NSCLC.²⁴

Quality of included trials

In the three studies of CMLND versus SS allocation concealment and method of randomisation were found to be adequate (in some cases after contact with the authors).¹²,¹³ Further quality details of the trials are shown in table 3. None of the included studies contained a clear statement that they had conducted an intention to treat analysis. However, this information was inferred from information provided about analysis and results for some of the trials. For two trials there were no crossovers after

Table 3 Methodological quality of included trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation concealment</th>
<th>Method of randomisation</th>
<th>Blinded assessment of outcome</th>
<th>Description of withdrawals</th>
<th>Intention to treat analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRC, UK²⁵</td>
<td>Adequate</td>
<td>Not reported</td>
<td>None described</td>
<td>No description</td>
<td>Yes*</td>
</tr>
<tr>
<td>NCI, USA²⁶</td>
<td>Adequate</td>
<td>Not reported</td>
<td>None described</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>National Cancer Institute of Canada trial, North America²⁶</td>
<td>Adequate†</td>
<td>Adequate†</td>
<td>No</td>
<td>No loss†</td>
<td>Yes†</td>
</tr>
<tr>
<td>RTOG 89–01²⁷</td>
<td>Not reported</td>
<td>Not reported</td>
<td>None described</td>
<td>Incomplete description</td>
<td>No</td>
</tr>
<tr>
<td>University of Athens, Greece²⁴</td>
<td>Not reported</td>
<td>Not reported</td>
<td>None described</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Intergroup 0139 trial (RTOG 93–09), North America²⁷</td>
<td>Not reported</td>
<td>Not reported</td>
<td>None described</td>
<td>Incomplete description</td>
<td>No</td>
</tr>
<tr>
<td>Yamaguchi University (VATS v open)²⁸</td>
<td>Inadequate</td>
<td>Inadequate</td>
<td>None described</td>
<td>No</td>
<td>Unclear</td>
</tr>
<tr>
<td>Lung Cancer Study Group trial, North America²⁹</td>
<td>Adequate</td>
<td>Not reported</td>
<td>None described</td>
<td>Yes (N.B. 18% loss in each group)</td>
<td>Unclear</td>
</tr>
<tr>
<td>University of Munich³⁰</td>
<td>Adequate†</td>
<td>Adequate†</td>
<td>Yes†</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Yamaguchi University³¹</td>
<td>Adequate†</td>
<td>Adequate†</td>
<td>Yes†</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Sun Yat-San University of Medical Sciences, Guangzhou³²</td>
<td>Adequate†</td>
<td>Adequate†</td>
<td>None described</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*Unclear if losses to follow up.
†Confirmed by contacting authors.
‡RTOG, Radiation Therapy Oncology Group.
§Investigators undertaking follow up blinded from treatment group.

Table 4 Overall survival and progression free survival for trials comparing surgery (± other treatment) with non-surgical treatment

<table>
<thead>
<tr>
<th>Study</th>
<th>Arm 1</th>
<th>Arm 2</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRC, UK²⁵</td>
<td>4 year OS 23%, Squamous cell subgroup analysis 30%</td>
<td>4 year OS 7%, Squamous cell subgroup analysis 6%</td>
<td>3.27 (0.74 to 14.42), p = 0.12</td>
</tr>
<tr>
<td>NCI, USA²⁶</td>
<td>Initially inoperable, radiotherapy</td>
<td>Initially inoperable, radiotherapy</td>
<td>5.10 (0.68 to 38.29), p = 0.11</td>
</tr>
<tr>
<td>National Cancer Institute of Canada, North America²⁶</td>
<td>Chemotherapy then surgery 2 year OS 44%</td>
<td>Radiotherapy</td>
<td>1.42 (0.42 to 4.81), p = 0.57</td>
</tr>
<tr>
<td>Intergroup 0139 trial (RTOG 93–09), North America²⁷</td>
<td>Concurrent chemotherapy and radiotherapy then surgery Treatment deaths 14 3 year OS 29% 3 year OS 38%</td>
<td>Concurrent chemotherapy and radiotherapy then surgery Treatment deaths 3 3 year OS 19% 3 year OS 33%</td>
<td>1.58 (0.39 to 6.38), p = 0.52</td>
</tr>
</tbody>
</table>

OS, overall survival; PFS, progression free survival; RTOG, Radiation Therapy Oncology Group; RR, relative risk; CI, confidence interval.
randomisation but there were a number of exclusions after randomisation, not strictly adhering to intention to treat analysis.\textsuperscript{11,13,15}

**Data synthesis**

**Trials comparing surgery (± other treatment) with non-surgical treatment arm**

The results of four trials included in this category are shown in table 4.\textsuperscript{16,20–27} These trials were diverse in terms of the interventions and populations and therefore not suitable for pooled analysis. In none of the studies was the surgical treatment arm found to be significantly superior to the non-surgical group in terms of overall survival. The authors intended to conduct a pooled analysis of the two studies comparing chemotherapy followed by surgery with chemotherapy followed by radiotherapy but there was significant statistical heterogeneity between these studies (\chi^2 statistic for homogeneity 3.65, \(p = 0.06\)) so a pooled analysis was not performed. The results of these individual studies are shown in fig 2. In one study there were two treatment related deaths in the chemotherapy/surgery group and one in the chemotherapy/radiotherapy group (relative risk (RR) 2.21 (95% CI 0.21 to 23.08), \(p = 0.51\)).\textsuperscript{17} Treatment related deaths were not described in the other trial.\textsuperscript{18}

**Studies comparing different surgical approaches for lung cancer**

**Mediastinal lymphadenectomy**

A pooled analysis (fixed effects model) was conducted comparing hazards (or mortality rate) over the first 4 years after randomisation for the three studies included in this category. There was a significant reduction in the risk of death in the group undergoing CMLND (fig 3) with a pooled hazard ratio estimated at 0.78 (95% CI 0.65 to 0.93; \(p = 0.005\)). There was no significant statistical heterogeneity between studies being pooled (\chi^2 statistic for homogeneity = 0.13; \(p = 0.94\)). A subgroup analysis by stage was not conducted due to the possibility of stage migration in the CMLND group (Will Rogers phenomenon).\textsuperscript{18} In one trial there was a non-significant trend to improved disease free survival in the CMLND group with a median follow up of 47.5 months; the hazard ratio was reported to be 0.82 (95% CI 0.54 to 1.27).\textsuperscript{19} The remaining trials did not report time to event data for disease recurrence so meta-analysis was not possible.

None of the trials individually found a significant difference between the groups in terms of 30 day operative mortality. In the pooled analysis the relative risk was 0.86 (95% CI 0.19 to 3.77, \(p = 0.84\)) without significant statistical heterogeneity between studies being pooled (\(p = 0.39\)).

**Limited resection versus lobectomy**

In the study comparing limited resection with lobectomy in patients with peripheral stage I NSCLC, limited resection was associated with an increased risk of locoregional recurrence (RR 2.84 (95% CI 1.32 to 6.1), \(p = 0.007\)).\textsuperscript{20,21} There was also a trend to improved overall survival with 5 year survival of 74% in the lobectomy group and 55% in the limited resection group.\textsuperscript{22} The hazard ratio was 0.67 (95% CI 0.44 to 1.02, \(p = 0.062\)). There was a trend to an increased mortality rate from cancer in the limited resection group compared with the lobectomy group (RR 1.46 (95% CI 0.87 to 2.45), \(p = 0.15\)). It is not clear if the results presented above were based on an intention to treat analysis; however, the investigators involved in the Lung Cancer Study Group trial also conducted an analysis that included all patients randomised but actual results were not provided in the published report.\textsuperscript{22,23} There was less reduction (from the preoperative level) in forced expiratory volume in 1 second at 12–18 months (mean % difference) in the limited resection group than in the lobectomy group. The mean difference between groups was 5.91 (95% CI 0.29 to 11.53, \(p = 0.04\)). However, this difference is of doubtful clinical significance and, furthermore, less than 67% of participants had lung function results available at 12–18 months. There were two postoperative deaths in the lobectomy group and one in the limited resection group, but these figures were for all 276 individuals randomised and it was not clear from the report\textsuperscript{22} what the denominator was for each group.

**VATS lobectomy versus conventional lobectomy**

In the one study in this category the 5 year survival rate was 85% in the open group and 90% in the VATS group (RR 1.09 (95% CI 0.91 to 1.23, \(p = 0.46\)).\textsuperscript{24}
Although the Lung Cancer Study Group trial showed that there was a significant increase in local recurrence in the limited resection group, the trend to a reduction in the rate of death with cancer and death from all causes in the lobectomy group did not reach statistical significance at the conventional 5% level. The study was designed to show equivalence between the two groups and therefore a more conservative p value of p > 0.1 was used as acceptable evidence of equivalence. However, the 95% confidence intervals for the hazard ratio for 5 year overall survival are wide (0.44 to 1.02) and encompass equivalence. Likewise, they do not exclude a clinically important difference between the two groups.

The results of studies comparing CMLND with SS are of particular interest with respect to the efficacy of surgery in general and future surgical practice. In the pooled analysis of the three studies there was a significant reduction in death from all causes in the group undergoing CMLND. These results suggest that the risk of dying on any given day (given survival to that point) is 78% (95% CI 65 to 93) for the CMLND group compared with the SS group.

The quality of the primary studies should be taken into account when interpreting the results of this review. Several studies in this review have some methodological weaknesses that represent serious threats to the validity of the findings. In particular, the Lung Cancer Study Group trial reported high rates of losses to follow up in both groups and did not clearly state whether patients were analysed according to treatment received or treatment assigned. In addition, blinded assessment of outcome was not undertaken in this study and the high local recurrence rate in the limited resection group could, to some extent, reflect a detection bias. Furthermore, several trials excluded participants after randomisation in a manner that would not strictly fulfil the criteria for an intention to treat analysis. It is difficult to draw any conclusions about the role of VATS versus conventional lobectomy because the only study included in this review was small and the analysis was not by intention to treat.

Few trials included in this review have described the experience of the surgeons involved in performing surgery. The efficacy of the intervention may be influenced by the experience of the surgeons. This information is required when making judgements about the generalisability of any findings.

In summary, the current evidence from RCTs neither supports nor discounts the survival benefit of surgery for NSCLC. However, as more extensive (complete) surgery appears superior to less, by inference some surgery might be better than no surgery. In particular, compared with limited resection, lobectomy was shown to reduce the rate of local recurrence in individuals with stage I NSCLC in one study. CMLND appears to improve survival compared with SS in individuals with resected NSCLC. The results of the American College of Surgeons Oncology Group Z30 trial will be important to further clarify this issue. Similarly, the results of ongoing trials should help to clarify the role of surgery following induction chemotherapy with or without radiotherapy for patients with stage IIIA (N2) NSCLC. Further details of ongoing trials identified by this review are outlined elsewhere. If ongoing trials show that surgery does not significantly improve survival after induction chemotherapy with or without radiotherapy in patients with stage IIIA (N2) NSCLC, then it may be reasonable to conduct further RCTs comparing surgery with radiotherapy or chemoradiation in selected groups of patients with earlier stage NSCLC—for example, in older patients in whom the perioperative mortality of surgery is on average 6% for patients aged 70–79 years and 8% for those aged 80 years and older, or in patients with reduced respiratory reserve.

ACKNOWLEDGEMENTS

The authors thank the Iberoamerican Cochrane Center for assistance with database searches and Dr Sera Tort, Dr Marta Roque and Dr Elinor Thompson (coordinators of the Cochrane Lung Cancer Group) for assistance with protocol development and editing of the review. They also acknowledge the help provided by authors of primary studies who have responded to correspondence and provided additional information. Some of the narrative in the text, tables 1, 2 and 3, and figures 2 and 3 of the present article also appear in the Cochrane Review (© Cochrane Library, reproduced with permission).

Authors' affiliations

G Wright, Cardiothoracic Care Centre, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
R L Manser, D Hart, Department of Respiratory Medicine, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
R L Manser, Clinical Epidemiology and Health Service Evaluation Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia
G Byrnes, Centre for Genetic Epidemiology, The University of Melbourne, Parkville, Victoria, Australia
D A Campbell, Monash Institute of Health Services Research, Monash Medical Centre, Clayton, Victoria, Australia
Dr Manser is supported by an Australian National Health and Medical Research Council postgraduate scholarship (scholarship number 201173).

Competing interests: none.

REFERENCES

High prevalence of PE in patients with unexplained exacerbation of COPD

This single centre study enrolled 197 patients with COPD requiring admission to hospital for an unexplained acute exacerbation. Patients with any evidence of lower respiratory tract infection, pneumothorax, and those requiring invasive ventilation were excluded. Patients with clinical and radiological findings deemed out of keeping with the degree of hypoxaemia were included. All patients were investigated with computed tomogram pulmonary angiography (CTPA) and venous lower limb ultrasonography.

Evidence of pulmonary embolus (PE) was found in 49 of the 197 patients (25%, 95% CI 19 to 32). This is consistent with previously published data. The diagnosis of PE was determined by positive CTPA and deep vein thrombosis (DVT) on ultrasound in 19 patients; 24 patients had a positive CTPA alone and six with a negative CTPA had DVT seen on ultrasound. The patients were retrospectively categorised into low, intermediate, and high probability according to the Geneva score. Eleven of the 119 patients (9%) in the low probability group had PE, 35 of 75 patients (46%) in the intermediate probability category had PE, and all three in the high probability group had PE.

The diagnosis of PE could not therefore be excluded on the basis of a low probability Geneva score. The only reliable risk factors identified in this study group were previous thromboembolism, malignancy, and a decreased arterial carbon dioxide tension compared with baseline.

A Patel
Senior Clinical Fellow, Royal Free Hospital, London, UK; anantpatel478@yahoo.co.uk
Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials
G Wright, R L Manser, G Byrnes, D Hart and D A Campbell

Thorax 2006 61: 597-603 originally published online January 31, 2006
doi: 10.1136/thx.2005.051995

Updated information and services can be found at:
http://thorax.bmj.com/content/61/7/597

These include:

References
This article cites 28 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/61/7/597#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Clinical trials (epidemiology) (557)
Lung cancer (oncology) (670)
Lung cancer (respiratory medicine) (670)
Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/